Anika Therapeutics was granted regulatory approval in India for MONOVISC® single injection viscosupplement to treat osteoarthritis pain in all human synovial joints. The product will be marketed in the region by Modi-Mundipharma under terms of a multi-year exclusive agreement.
Global distribution of MONOVISC is Anika’s primary international orthobiologics revenue driver. Presently available in Canada, Europe and the U.S., MONOVISC will be expanded into Australia, India, New Zealand and other ex-U.S. markets over six to nine months.
Source: Anika Therapeutics, Inc.
Anika Therapeutics was granted regulatory approval in India for MONOVISC® single injection viscosupplement to treat osteoarthritis pain in all human synovial joints. The product will be marketed in the region by Modi-Mundipharma under terms of a multi-year exclusive agreement.
Global distribution of MONOVISC is Anika's primary international...
Anika Therapeutics was granted regulatory approval in India for MONOVISC® single injection viscosupplement to treat osteoarthritis pain in all human synovial joints. The product will be marketed in the region by Modi-Mundipharma under terms of a multi-year exclusive agreement.
Global distribution of MONOVISC is Anika’s primary international orthobiologics revenue driver. Presently available in Canada, Europe and the U.S., MONOVISC will be expanded into Australia, India, New Zealand and other ex-U.S. markets over six to nine months.
Source: Anika Therapeutics, Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.